NASDAQ:ALXNAlexion Pharmaceuticals Stock Price, Forecast & News

Alexion Pharmaceuticals' stock was trading at $83.77 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ALXN stock has increased by 35.6% and is now trading at $113.57. View which stocks have been most impacted by Coronavirus.

24 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings, 16 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alexion Pharmaceuticals.

Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Alexion Pharmaceuticals.

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) posted its quarterly earnings results on Wednesday, May, 6th. The biopharmaceutical company reported $3.22 earnings per share for the quarter, topping analysts' consensus estimates of $2.71 by $0.51. The biopharmaceutical company had revenue of $1.44 billion for the quarter, compared to analyst estimates of $1.36 billion. Alexion Pharmaceuticals had a return on equity of 21.96% and a net margin of 44.83%. The business's quarterly revenue was up 26.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.39 EPS. View Alexion Pharmaceuticals' earnings history.

Alexion Pharmaceuticals updated its FY20 earnings guidance on Wednesday, May, 6th. The company provided earnings per share (EPS) guidance of $10.45-$10.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $10.96. The company issued revenue guidance of $5.23-$5.33 billion, compared to the consensus revenue estimate of $5.51 billion.

24 brokerages have issued twelve-month target prices for Alexion Pharmaceuticals' stock. Their forecasts range from $110.00 to $180.00. On average, they expect Alexion Pharmaceuticals' stock price to reach $143.95 in the next twelve months. This suggests a possible upside of 26.8% from the stock's current price. View analysts' price targets for Alexion Pharmaceuticals.

News headlines about ALXN stock have trended negative on Monday, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Alexion Pharmaceuticals earned a media sentiment score of -2.1 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Alexion Pharmaceuticals.

Alexion Pharmaceuticals saw a decline in short interest in the month of June. As of June 15th, there was short interest totaling 4,500,000 shares, a decline of 5.3% from the May 31st total of 4,750,000 shares. Based on an average daily volume of 2,620,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 2.1% of the company's stock are short sold. View Alexion Pharmaceuticals' Current Options Chain.

Some companies that are related to Alexion Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Alibaba Group (BABA), Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Micron Technology (MU), Celgene (CELG), AbbVie (ABBV), Walt Disney (DIS), Visa (V) and Biogen (BIIB).

Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN."

Alexion Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.03%), Fulton Bank N. A. (0.01%) and Municipal Employees Retirement System of Michigan (0.00%). Company insiders that own Alexion Pharmaceuticals stock include Aradhana Sarin, Bros Advisors Lp Baker, Daniel Bazarko, Indrani Lall Franchini, Ludwig Hantson and Paul J Clancy. View institutional ownership trends for Alexion Pharmaceuticals.

ALXN stock was sold by a variety of institutional investors in the last quarter, including Fulton Bank N. A.. View insider buying and selling activity for Alexion Pharmaceuticals.

ALXN stock was bought by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Municipal Employees Retirement System of Michigan. View insider buying and selling activity for Alexion Pharmaceuticals.

Shares of ALXN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ALXN stock can currently be purchased for approximately $113.57.

Alexion Pharmaceuticals has a market capitalization of $25.08 billion and generates $4.99 billion in revenue each year. The biopharmaceutical company earns $2.40 billion in net income (profit) each year or $9.74 on an earnings per share basis. Alexion Pharmaceuticals employs 3,082 workers across the globe.

The official website for Alexion Pharmaceuticals is www.alexion.com.

Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]